Long-term damage assessment in patients with microscopic polyangiitis and renal-limited vasculitis using the Vasculitis Damage Index

REFERENCES

• Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic anti-bodies. Lancet. 2006;368:404–18.
   PubMed Web of Science ®Google Scholar
• Chen M, Kallenberg CG. ANCA-associated vasculitides—advances in pathogenesis and treatment. Nat Rev Rheumatol. 2010;6:653–64.
   PubMed Web of Science ®Google Scholar
• Wiik A. Rational use of ANCA in the diagnosis of vasculitis. Rheumatology (Oxford). 2002;41:481–3.
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Uezono S, Hisanaga S, Fukudome K, Kobayashi S, Suzuki K, et al. Incidence of ANCA-associated primary renal vasculitis in Miyazaki Prefecture: the first population-based, retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol. 2006;1:1016–22.
   PubMed Web of Science ®Google Scholar
• Watts RA, Scott DG, Jayne DRW, Ito-Ihara T, Muso E, Fujimoto S, et al. Renal vasculitis in Japan and UK-are there differences in epidemiology and clinical phenotype? Nephrol Dial Trans-plant. 2008;23:3743–5.
   Google Scholar
• Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoanti-bodies. N Engl J Med. 2003;349:36–44.
   Google Scholar
• Knight A, Askling J, Granath F, Sparen P, Ekbom A. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis. 2004;63:1307–11.
   Google Scholar
• Itabashi M, Takei T, Yabuki Y, Suzuk Hi, Ando M, Akamatsu M, et al. Clinical outcome and prognosis of anti-neutrophil cyto-plasmic antibody-associated vasculitis in Japan. Nephron Clin Pract. 2010;115:c21–c27.
   Google Scholar
• Itabashi M, Takei T, Morito T, Yabuki Y, Suzuki H, Ando M, et al. Estimation of BVAS in patients with microscopic polyan-giitis in Japan. Clin Rheumatol. 2011;30(11):1499–505.
   PubMed Web of Science ®Google Scholar
• Exley AR, Bacon PA, Luqmani RA. Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitide. Arthritis Rheum. 1997;40:371–80.
   Google Scholar
• Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum. 2005;52:2168–78.
   PubMed Web of Science ®Google Scholar
• Ozaki S, Atsumi T, Hayashi T, Ishizu A, Kobayashi S, Kumagai S, et al. Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol. 2012;22:394–404.
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum. 1994;37: 187–92.
   PubMed Web of Science ®Google Scholar
• Flossmann 0, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P, et al. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis. 2007;66:283–92.
   PubMed Web of Science ®Google Scholar
• Mukhtyar CB, Flossmann 0, Luqmani RA. Clinical and biolog-ical assessment in systemic necrotizing vasculitides. Clin Exp Rheumatol. 2006;24:592–9.
   Google Scholar
• Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regi-men for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med. 2003;114:463–9.
   PubMed Web of Science ®Google Scholar
• Suppiah R, Flossman 0, Mukhtyar C, Alberici F, Baslund B, Brown D, et al. Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. Ann Rheum Dis. 2011;70: 80–5.
   Google Scholar
• Seo P, Luqmani RA, Flossmann 0, Hellmich B, Herlyn K, Hoffman GS, et al. The future of damage assessment in vasculitis. J Rheumatol. 2007;34:1357–71.
   Google Scholar
• Mohammad AJ, Bakoush 0, Sturfelt G. The extent and pattern of organ damage in small vessel vasculitis measured by the Vas-culitis Damage Index (VDI). Scand J Rheumatol. 2009;38: 268–75.
   Google Scholar
• Karnali S, Erer B, Artim-Esen B, Gul A, Ocal L, Konice M, et al. Predictors of damage and survival in patients with Wegener's granulomatosis: analysis of 50 patients. J Rheumatol. 2010;37: 374–8.
   Google Scholar
• Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology. 2002;41: 572–81.
   PubMed Web of Science ®Google Scholar
• Exley AR, Carruthers DM, Luqmani RA, Kitas GD, Gordon C, Janssen BA, et al. Damage occurs early in systemic vasculitis and is an index of outcome. QJM. 1997;90:391–9.
   PubMed Web of Science ®Google Scholar
• Brijker F, Magee CC, Tervaert JW, O'Neill S, Walshe JJ. Out-come analysis of patients with vasculitis associated with antine-utrophil cytoplasmic antibodies. Clin Nephrol. 1999;52:344–51.
   Google Scholar